Kristie L. Kahl

We spoke with two members of the Moving Mountains for Multiple Myeloma team.

The American Cancer Society issued an updated guideline recommendation that now calls for screening to begin at age 45 for individuals at average risk for colorectal cancer.

Understanding one’s biomarkers, such as microsatellite stable (MSS) or instable (MSI) status in tumors, is key in understanding how a patient with colorectal cancer may be treated.

The Food and Drug Administration (FDA) granted a priority review to Keytruda (pembrolizumab) in combination with chemotherapy as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression, according to Merck, the manufacturer of the anti-PD-1 agent.

At the GI Cancer Patient Summit, a panel of caregivers drew upon personal experience to offer advice and discuss what more can be done for individuals in this role of the cancer journey.

We spoke with veteran journalist Neil Canavan about his book, A Cure Within: Scientists Unleashing the Immune System to Kill Cancer.

These discussions should include information about the cancer itself, as well as treatment options, side effects, prognosis, and most importantly, the patient’s values.

In the QUADRA study, treatment with Zejula (niraparib) demonstrated durable responses among women with relapsed or refractory ovarian cancer, regardless of BRCA mutation.

According to findings from the ASCO Annual Meeting, insurance disparities still exist, and may even contribute to cancer-specific and comorbidity-associated mortalities in patients with early-stage non-small cell lung cancer.

Phase 2 study results showed that patients with metastatic or unresectable, FGFR-positive bladder cancer may have a third-line option for treatment.

Researchers identified six gene variations that play an important role in the treatment and surveillance of children with medulloblastoma, for which they developed screening and counseling recommendations.

Lynch syndrome – a hereditary condition that increases a person’s risk for developing several types of cancer – is common among people with microsatellite instability-high (MSI-H) tumors, linking it to several new cancer types, according to large genomic study results presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

In this episode of CURE Talks Cancer, we spoke with colorectal cancer survivor Danielle Ripley-Burgess and childhood development specialist Leslie Welch about how parents or caregivers facing a cancer diagnosis can have discussions with children of any age about cancer.

In the Keynote-042 trial, researchers found a four- to eight-month overall survival benefit among patients with non-small cell lung cancer (NSCLC), which was correlated with higher levels of PD-L1 expression, however, further study is warranted.

The application is seeking approval for GARDASIL 9 to be used in women and men aged 27 to 45 years for the prevention of certain cancers and diseases caused by the nine human papillomavirus (HPV) types covered by the vaccine.

In a presentation at the 2018 ASCO Annual Meeting, researchers from Kaiser Permanente also found that women were almost twice as likely to die from the disease compared with non-cancer deaths.

The Food and Drug Administration (FDA) approved Venclexta (venetoclax) in combination with Rituxan (rituximab) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the genetic mutation 17p deletion, who have received at least one prior therapy.

Racial disparities in palliative and hospice care beliefs appear to influence early integration in to standard oncologic care for patients with advanced lung cancer.

An expert from Texas Oncology offers perspective on findings from the CCGA study – presented at the 2018 ASCO Annual Meeting – which may support the use of a blood test to detect lung cancer earlier.

In this week’s episode of CURE Talks Cancer, we spoke with lung cancer survivor Taylor Bell Duck about her cancer journey and celebrating survivorship 10 years later.

The Food and Drug Administration (FDA) approved Leukine (sargramostim) for the treatment of adult and pediatric patients who are exposed to myelosuppressive doses of radiation that results in a hematopoietic subsyndrome of acute radiation syndrome.

The Food and Drug Administration (FDA) approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to reduce the risk for febrile neutropenia in patients treated with chemotherapy in certain types of cancer.

The House of Representatives has passed a controversial right-to-try bill that would give critically ill patients quick access to experimental drugs.

Despite improved outcomes, the researchers also found that side effects with checkpoint inhibition often affected the dermatologic, gastrointestinal, pulmonary, renal, endocrine and hepatic systems in patients.

In this week’s episode of CURE Talks Cancer, we spoke with Matt Lashey, creator and CEO of the chemoWave app, which is designed to manage cancer symptoms and conditions by keeping track of a patient’s overall well-being to understand how their experiences may be related to feeling better or worse during treatment.

Although still in early phases, an oncolytic virus, called DNX-2401, may be a groundbreaking therapy in pediatric patients with diffuse intrinsic pontine gliomas.

CURE spoke with a childhood development specialist and colorectal cancer survivor to offer firsthand advice and tips on how to discuss a cancer diagnosis with children of any age.

We spoke with an expert about navigating at-home genetic testing kits, which are growing in popularity.

During the fourth annual Virginia Vines event, the V Foundation helped raise funds for cancer research and provided education on recent advancements in the treatment landscape.

The Food and Drug Administration (FDA) granted approval to Darzalex (daratumumab) in combination with Velcade (bortezomib), melphalan and prednisone – also known as VMP – for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).